Gotham Asset Management LLC Purchases 20,624 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• Gotham Asset Management LLC significantly increased its stake in Regeneron Pharmaceuticals by 180.5% during the first quarter, acquiring an additional 20,624 shares to total 32,047 shares worth approximately $20.3 million.
• Several institutional investors, including Vanguard Group, Goldman Sachs, and Amundi, have also raised their stakes in Regeneron, indicating strong interest from hedge funds, which collectively own 83.31% of the stock.
• Regeneron Pharmaceuticals reported an earnings per share (EPS) of $12.89 for the last quarter, which surpassed analyst expectations, and the company recently announced a quarterly dividend of $0.88, yielding 0.6%.

Gotham Asset Management LLC increased its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 180.5% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 32,047 shares of the biopharmaceutical company's stock after acquiring an additional 20,624 shares during the period. Gotham Asset Management LLC's holdings in Regeneron Pharmaceuticals were worth $20,325,000 at the end of the most recent reporting period.

Several other hedge funds have also bought and sold shares of the business. DnB Asset Management AS lifted its stake in shares of Regeneron Pharmaceuticals by 40.0% in the first quarter. DnB Asset Management AS now owns 50,127 shares of the biopharmaceutical company's stock worth $31,792,000 after buying an additional 14,323 shares in the last quarter. AQR Capital Management LLC lifted its position in Regeneron Pharmaceuticals by 13.9% during the first quarter. AQR Capital Management LLC now owns 235,950 shares of the biopharmaceutical company's stock valued at $148,665,000 after purchasing an additional 28,865 shares during the period. Advisors Asset Management Inc. lifted its position in Regeneron Pharmaceuticals by 3.9% during the first quarter. Advisors Asset Management Inc. now owns 5,369 shares of the biopharmaceutical company's stock valued at $3,405,000 after purchasing an additional 204 shares during the period. Amundi lifted its position in Regeneron Pharmaceuticals by 3.4% during the first quarter. Amundi now owns 1,603,901 shares of the biopharmaceutical company's stock valued at $979,794,000 after purchasing an additional 52,166 shares during the period. Finally, Adage Capital Partners GP L.L.C. lifted its position in Regeneron Pharmaceuticals by 109.1% during the first quarter. Adage Capital Partners GP L.L.C. now owns 92,745 shares of the biopharmaceutical company's stock valued at $58,822,000 after purchasing an additional 48,396 shares during the period. Institutional investors own 83.31% of the company's stock.

Regeneron Pharmaceuticals Price Performance

REGN stock traded down $1.91 during trading on Tuesday, hitting $556.53. 850,408 shares of the company's stock traded hands, compared to its average volume of 1,102,246. Regeneron Pharmaceuticals, Inc. has a 52 week low of $476.49 and a 52 week high of $1,170.58. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.72 and a current ratio of 4.60. The business has a fifty day simple moving average of $563.25 and a 200 day simple moving average of $582.14. The stock has a market capitalization of $58.99 billion, a price-to-earnings ratio of 14.03, a P/E/G ratio of 1.92 and a beta of 0.35.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its quarterly earnings data on Friday, August 1st. The biopharmaceutical company reported $12.89 EPS for the quarter, beating the consensus estimate of $8.43 by $4.46. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. The business had revenue of $3.68 billion during the quarter, compared to analyst estimates of $3.30 billion. During the same quarter last year, the business earned $11.56 earnings per share. Regeneron Pharmaceuticals's quarterly revenue was up 3.6% compared to the same quarter last year. As a group, research analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, September 3rd. Shareholders of record on Monday, August 18th were given a dividend of $0.88 per share. The ex-dividend date was Monday, August 18th. This represents a $3.52 annualized dividend and a yield of 0.6%. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is 8.87%.

Analyst Upgrades and Downgrades

A number of analysts have commented on the stock. Argus cut shares of Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Monday, June 30th. Truist Financial decreased their price target on shares of Regeneron Pharmaceuticals from $940.00 to $812.00 and set a "buy" rating on the stock in a research report on Monday, August 11th. Sanford C. Bernstein increased their price target on shares of Regeneron Pharmaceuticals from $753.00 to $781.00 and gave the stock an "outperform" rating in a research report on Wednesday, August 27th. Rothschild & Co Redburn started coverage on shares of Regeneron Pharmaceuticals in a research report on Thursday, August 14th. They issued a "buy" rating and a $890.00 price target on the stock. Finally, JPMorgan Chase & Co. decreased their price target on shares of Regeneron Pharmaceuticals from $950.00 to $800.00 and set an "overweight" rating on the stock in a research report on Monday, June 9th. Three research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $817.67.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.